Protagonist Therapeutics (PTGX) Receivables - Net (2017 - 2026)

Protagonist Therapeutics (PTGX) has 10 years of Receivables - Net data on file, last reported at $53.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net changed N/A year-over-year to $53.7 million; the trailing twelve-month figure through Mar 2026 stood at $53.7 million (changed N/A YoY), and the FY2025 full-year result was $121000.0, down 99.93% from the prior year.
• Receivables - Net grew to $53.7 million in Q1 2026, from $121000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $165.0 million in Q4 2024 to a low of $10000.0 in Q4 2022.
• A 5-year average of $24.5 million and a median of $123000.0 in 2022 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net surged 529.38% in 2022 and plunged 99.93% in 2025, its largest moves.
• Tracing PTGX's Receivables - Net over 5 years: stood at $10000.0 in 2022, then jumped by 290.0% to $39000.0 in 2023, then soared by 422976.92% to $165.0 million in 2024, then sank by 99.93% to $121000.0 in 2025, then jumped by 44249.59% to $53.7 million in 2026.
• Business Quant data shows PTGX's Receivables - Net at $53.7 million in Q1 2026, $121000.0 in Q4 2025, and $583000.0 in Q3 2025.